Besinsel glikotoksinler ve mamalar

İleri glikasyon ürünleri, proteinlerin, lipidlerin ve nükleik asidlerin, enzimatik olmayan bir yoldan endojen glikasyonu sonucunda oluşan kompleks bir grup olup eksojen olarak sigara içme gibi yollarla da alınabilir ve glikotoksin adını alır. Diyetle alınan glikotoksinlerin kısıtlanmasının, hem hayvan deneylerinde hem de diyabetli hastalar ve metabolik hastalıklarda yararlı olduğu konusundaki bilgiler giderek artmaktadır. Bebek mamalarının içeriği ve imalat yöntemleri glikotoksin oluşması için çok uygun bir ortam oluşturmakta olup bebek mamalarındaki glikotoksin miktarı anne sütünden yüzlerce misli fazla bulunabilir. Sağlıklı bebeklerde yapılmış olan az sayıda, kısıtlı çalışmada glikotoksinlerin erken çocukluk döneminde sağlık üzerine olumsuz bir etkisi gösterilememiştir. Ancak, riskli bebeklerde ve uzun dönemde erişkin sağlığı üzerindeki olası etkiler henüz bilinmemektedir.

Dietary glycotoxins and infant formulas

Advanced glycation end products constitute a complex group of compounds derived from the nonenzymatic glycation of proteins, lipids, and nucleic acids formed endogenously, but also from exogenous supplies such as tobacco smoking (glycotoxins). Accumulating evidence underlies the beneficial effect of the dietary restriction of glycotoxins in animal studies and also in patients with diabetic complications and metabolic diseases. Composition of infant formulas and their processing methods render an extraordinary favorable milieu for the formation of glycotoxins, and the content of glycotoxins in infant formula exceeds that of breast milk by hundred folds. Data from a limited number of short-term small studies in healthy infants do not provide direct evidence of acute negative health effects of glycotoxins in early infancy. However, the effects in sensitive groups on the state of future health in adulthood remain unclear.

PDF

___

Kaanane A, Labuza TP. The Maillard reaction in foods. Prog Clin Biol Res 1989; 304: 301-27.
O'Brien J, Morrissey PA. Nutritional and toxicological as- pects of the Maillard's browning reaction in foods. Crit Rev Food Sci Nutr 1989; 28: 211-48. [CrossRef ]
Palimeri S, Palioura E, Diamanti-Kandarakis E. Current pers- pectives on the health risks associated with the consumption of advanced glycation end products: recommendations for die- tary management. Diabetes Metab Syndr Obes 2015; 8: 415-26.
Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997; 94: 13915-20. [CrossRef ]
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end- products: a review. Diabetologia 2001; 44: 129-46. [CrossRef ]
Goldberg T, Cai W, Peppa M , et al. Advanced glycation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-91. [CrossRef ]
Koschinsky T, He CJ, Mitsubishi T, et al. Orally absorbed re- active glycation products (glytoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-9. [CrossRef ]
Gugliucci A, Bendayann M. Renal fate of circulating advan- ced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal tubular cells. Dia- betologia 1996; 39: 149-60. [CrossRef ]
Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor mediated endocytosis in hepatic sinusoidal Kupffer and en- dothelial cells. Biochem J 1997; 322: 567-73. [CrossRef ]
Matsumoto K, Sano H, Nagai R, et al. Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor dis- tinct from the macrophage scavenger receptor class A. Bioc- hem J 2000; 352: 233-40. [CrossRef ]
Poulsen MW, Hedegaard RV, Andersen JM, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 2013; 60: 10-37. [CrossRef ]
Goh SY, Cooper ME. Clinical review:The role of advanced glycation end products in progression and complications of di- abetes. J Clin Endocrinol Metab 2008; 93: 1143-52. [CrossRef]
Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005; 54: 2314-9. [CrossRef]
Uribarri J, Cai W, Ramdas M, et al. Restriction of advanced glycation end products improves insulin resistance in hu- man type 2 diabetes: potential role of AGER1 and SIRT1. Daibetes Care 2011; 34: 1610-6. [CrossRef ]
Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149-60. [CrossRef ]
Jensen LJ, Ostergaard J, Flyvbjerg A. AGE-RAGE and AGE Cross-link interaction: important players in the pathogene- sis of diabetic kidney disease. Horm Metab Res 2005; 37: 26-34. [CrossRef ]
Rai DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-80. [CrossRef ]
Santos JC, Valentim IB, de Araşjo OR, Ataide Tda R, Goulart MO. Development of nonalcoholic hepatopathy: contributi- ons of oxidative stress and advanced glycation end products. Int J Mol Sci 2013;14: 19846-66. [CrossRef ]
Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcolic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-9. [CrossRef ]
Yağmur E, Tacke F, Weiss C, et al. Elevation of Nepsilon- (carboxymethyl)lysine-modified advanced glycation end products in chronnic liver diseasis an indicator of liver cirr- hosis. Clin Biochem 2006; 39: 39-45. [CrossRef ]
Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol 2005; 62: 37-43. [CrossRef ]
Diamanti-Kandarakis E, Piperi C, Patsouris E, et al. Immu- nohistochemical localization of advanced glycation end- products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007; 127: 581-9. [CrossRef ]
Salahuddin P, Rabbani G, Khan RH. The role of advanced glycation end products in various types of neurodegenerati- ve disease: a therapeutic approach. Cell Mol Biol Lett 2014; 19: 407-37. [CrossRef ]
Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifi- able cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U SA 2014; 111: 4940-5. [CrossRef ]
Kandarakis SA, Piperi C, Topouzis F, Papavassiliou AG. Emer- ging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Ret Eye Res 2014; 42: 85- 102. [CrossRef ]
Kandarakis SA, Piperi C, Moschonas DP, Korkolopoulou P, Papalois A, Papavassiliou AG. Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. Exp Eye Res 2015; 137: 1-10. [CrossRef ]
Sharaf H, Matou-Nasri S, Wang Q, et al. Advanced glycation end-products increase proliferation, migration and invasi- on of the breast cancer cell line MDA-MB-231. Biochim Bi- ophys Acta 2015; 1852: 429-41. [CrossRef ]
Van Heijst JW, Niessen HW, Hoekmann K, Schalkwijk CG. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl) lysine and argpyri- midine. Ann N Y Acad Sci 2005; 1043: 725-33. [CrossRef ]
Jiao L, Weinstein SJ, Albanes D, et al. Evidence that serum le- vels of the soluble receptor for advanced glycation end pro- ducts are inversely associated with pancreatic canncer risk:a prospective study. Cancer Res 2011; 71: 3582-9. [CrossRef ]
Meerwaldt R, Graaff R, Oomen PH, et al. Simple non- invasive assessment of advanced glycation endproduct ac- cumulation. Diabetologia 2004; 47: 1324-30. [CrossRef ]
Petrovic R, Futas J, Chandoga J, Jakus V. Rapid and simple method for determination of Nepsilon-(carboxymethyl) lysine and Nepsilon-(carboxyethyl) lysine in urine using gas chromatography/mass spectrometry. Biomed Chromatogr 2005; 19: 649-54. [CrossRef ]
Jahan H, Choudhary MI. Glycation, carbonyl stress and AGEs inhibitors: a patent review. Expert Opin 2015; 25: 1267-84.
Banser A, Naafs JC, Hoorweg-Nijman JJG, van de Garde EMW, van der Vorst MMJ. Advanced glycation end products, measured in skin, vs, HbA1c in children with type 1 diabetes mellitus. Pediatric Diabetes 2015; 17: 426-32. [CrossRef ]
Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in food and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-6. [CrossRef ]
Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hyper- tensive rat. Diabetologia 1994; 37: 32-5. [CrossRef ]
Wilkinson-Berka JL, Jelly DJ, Koerner SM, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51: 3283-9. [CrossRef ]
Cheng G, Wang LL, Long L, et al. Beneficial effects of C36, a novel breaker of advanced glycation end products cross- links, on the cardiaovascular system of diabetic rats. Br J Pharmacol 2007; 152: 1196-206. [CrossRef ]
Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis indu- ced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30. [CrossRef ]
Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retiopathy in experi- mental diabetes. Diabetes 20012; 51: 2826-32.
Candido R, Forbes JM, Thomas MC, et al. A breaker of ad- vanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-92. [CrossRef ]
Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007; 106: S54-60. [CrossRef ]
Win MT, Yamamoto Y, Munesue S, et al. Regulation of RAGE for attenuating progression of diabetic vascular complicati- ons. Exp Diabetes Res 2012; 2012: 894605. [CrossRef ]
Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 2916-24. [CrossRef ]
Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complicati- ons. Expert Opin Investig Drugs 2008; 17: 983-96. [CrossRef ]
Sebeková K, Saavedra G, Zumpe C, Somoza V, Klenovicsová K, Birlouez-Aragon I. Plasma concentration and urinary exc- retion of N epsilon-(carboxymethyl) lysine in breast milk- and formula-fed infants. Ann N Y Acad Sci 2008; 1126: 177- 80. [CrossRef ]
Sebekova K, Klenovics KS, Sebekova KB. Advanced glyca- tion end products in infant formulas. İn: Preddy VR, Wat- son RR, Zibadi S (eds). Handbook of dietary and nutritional aspects of bottle feeding. Waningen Academic Publishers 2014.p.421-40.
Mericq V, Piccardo C, Cai W, et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 2010; 33: 2232-7. [CrossRef ]
Klenovics KS, Boor P, Somoza V, Celec P, Fogliano V, Sebeková K. Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption. PLoS One 2013; 8: e53056. [CrossRef ]
Schmidt IM, Damgaard IN, Boisen KA, et al. Increased kid- ney growth in formula-fed versus breast-fed healthy infants. Pediatr Nephrol 2004; 19: 1137-44. [CrossRef ]
Escribano J, Luque V, Ferre N, et al. Increased protein intake augments kidney volume and function in healthy infants. Kidney Int 2011; 79: 783-90. [CrossRef ]
Elmhiri G, Mahmoud DFD, Niquet-Leridon C, et al. Formu- la-derived advanced glycation end products are involved in the development of long-term inflammation and oxidative stress in kidney of IUGR piglets. Mol Nutr Food Res 2015; 59: 939-47.[CrossRef ]